Literature DB >> 24477852

Colonic immunopathogenesis of Clostridium difficile infections.

Charles Darkoh1, Bradley P Turnwald, Hoonmo L Koo, Kevin W Garey, Zhi-Dong Jiang, Samuel L Aitken, Herbert L DuPont.   

Abstract

There are major gaps in our understanding of the immunopathogenesis of Clostridium difficile infections (CDIs). In this study, 36 different biomarkers were examined in the stools of CDI and non-CDI patients using the Proteome Profiler human cytokine array assay and quantitative enzyme-linked immunosorbent assay. Diarrheal stools from patients with CDI (CDI-positive diarrheal stools) showed higher relative amounts of the following inflammatory markers than the diarrheal stools from CDI-negative patients (CDI-negative diarrheal stools): C5a, CD40L, granulocyte colony-stimulating factor, I-309, interleukin-13 (IL-13), IL-16, IL-27, monocyte chemoattractant protein 1, tumor necrosis factor alpha, and IL-8. IL-8 and IL-23 were present in a larger number of CDI-positive diarrheal stools than CDI-negative diarrheal stools. Th1 and Th2 cytokines were not significantly different between the CDI-positive and CDI-negative diarrheal stools. Lactoferrin and calprotectin concentrations were also higher in the CDI-positive diarrheal stools. Our results demonstrate that CDI elicits a proinflammatory host response, and we report for the first time that IL-23 is a major marker in CDI-positive diarrheal stools. IL-23 may explain the lack of a robust immunological response exhibited by a proportion of CDI patients and may relate to recurrence; the IL-23 levels induced during CDI in these patients may be inadequate to sustain the cellular immunity conferred by this cytokine in promoting the induction and proliferation of effector memory T cells.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24477852      PMCID: PMC3993122          DOI: 10.1128/CVI.00770-13

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  32 in total

Review 1.  The lineage decisions of helper T cells.

Authors:  Kenneth M Murphy; Steven L Reiner
Journal:  Nat Rev Immunol       Date:  2002-12       Impact factor: 53.106

Review 2.  A unique role for IL-23 in promoting cellular immunity.

Authors:  Carla S R Lankford; David M Frucht
Journal:  J Leukoc Biol       Date:  2003-01       Impact factor: 4.962

3.  Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology.

Authors:  S Dolwani; M Metzner; J J Wassell; A Yong; A B Hawthorne
Journal:  Aliment Pharmacol Ther       Date:  2004-09-15       Impact factor: 8.171

4.  Measurement of fecal lactoferrin as a marker of fecal leukocytes.

Authors:  R L Guerrant; V Araujo; E Soares; K Kotloff; A A Lima; W H Cooper; A G Lee
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

5.  Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes.

Authors:  K Bjerke; T S Halstensen; F Jahnsen; K Pulford; P Brandtzaeg
Journal:  Gut       Date:  1993-10       Impact factor: 23.059

6.  Assay of cytopathogenic toxins in cultured cells.

Authors:  M Thelestam; I Florin
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

7.  Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.

Authors:  B Oppmann; R Lesley; B Blom; J C Timans; Y Xu; B Hunte; F Vega; N Yu; J Wang; K Singh; F Zonin; E Vaisberg; T Churakova; M Liu; D Gorman; J Wagner; S Zurawski; Y Liu; J S Abrams; K W Moore; D Rennick; R de Waal-Malefyt; C Hannum; J F Bazan; R A Kastelein
Journal:  Immunity       Date:  2000-11       Impact factor: 31.745

8.  A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R.

Authors:  Christi Parham; Madaline Chirica; Jacqueline Timans; Elena Vaisberg; Marilyn Travis; Jeanne Cheung; Stefan Pflanz; Rebecca Zhang; Komal P Singh; Felix Vega; Wayne To; Janet Wagner; Anne-Marie O'Farrell; Terrill McClanahan; Sandra Zurawski; Charles Hannum; Daniel Gorman; Donna M Rennick; Robert A Kastelein; Rene de Waal Malefyt; Kevin W Moore
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

9.  Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation.

Authors:  Sunanda V Kane; William J Sandborn; Paul A Rufo; Anna Zholudev; James Boone; David Lyerly; Michael Camilleri; Stephen B Hanauer
Journal:  Am J Gastroenterol       Date:  2003-06       Impact factor: 10.864

Review 10.  Interleukin-4- and interleukin-13-mediated host protection against intestinal nematode parasites.

Authors:  Fred D Finkelman; Terez Shea-Donohue; Suzanne C Morris; Lucy Gildea; Richard Strait; Kathleen B Madden; Lisa Schopf; Joseph F Urban
Journal:  Immunol Rev       Date:  2004-10       Impact factor: 12.988

View more
  10 in total

1.  Clostridium difficile toxin B intoxicated mouse colonic epithelial CT26 cells stimulate the activation of dendritic cells.

Authors:  Tuxiong Huang; Gregorio Perez-Cordon; Lianfa Shi; Guangchao Li; Xingmin Sun; Xiaoning Wang; Jufang Wang; Hanping Feng
Journal:  Pathog Dis       Date:  2015-01-27       Impact factor: 3.166

Review 2.  Type 3 Immunity during Clostridioides difficile Infection: Too Much of a Good Thing?

Authors:  Mahmoud M Saleh; William A Petri
Journal:  Infect Immun       Date:  2019-12-17       Impact factor: 3.441

Review 3.  Host response to Clostridium difficile infection: Diagnostics and detection.

Authors:  Elena A Usacheva; Jian-P Jin; Lance R Peterson
Journal:  J Glob Antimicrob Resist       Date:  2016-09-20       Impact factor: 4.035

Review 4.  Neutrophil-mediated inflammation in the pathogenesis of Clostridium difficile infections.

Authors:  Shinsmon Jose; Rajat Madan
Journal:  Anaerobe       Date:  2016-04-05       Impact factor: 3.331

5.  Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes.

Authors:  Bradley T Endres; Eugénie Bassères; Mohammed Khaleduzzaman; M Jahangir Alam; Laurent Chesnel; Kevin W Garey
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

6.  Fecal calprotectin concentrations in cancer patients with Clostridium difficile infection.

Authors:  Taojun He; Samuel E Kaplan; Luz A Gomez; Xuedong Lu; Lakshmi V Ramanathan; Mini Kamboj; Yi-Wei Tang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-09-21       Impact factor: 3.267

7.  Fecal host biomarkers predicting severity of Clostridioides difficile infection.

Authors:  Makan Golizeh; Kaitlin Winter; Lucie Roussel; Marija Landekic; Mélanie Langelier; Vivian G Loo; Momar Ndao; Donald C Vinh
Journal:  JCI Insight       Date:  2021-01-11

8.  The xenobiotic sensing pregnane X receptor regulates tissue damage and inflammation triggered by C difficile toxins.

Authors:  Sarah L Erickson; Laurie Alston; Kristoff Nieves; Thomas K H Chang; Sridhar Mani; Kyle L Flannigan; Simon A Hirota
Journal:  FASEB J       Date:  2019-12-17       Impact factor: 5.191

9.  New Host-Directed Therapeutics for the Treatment of Clostridioides difficile Infection.

Authors:  Jourdan A Andersson; Alex G Peniche; Cristi L Galindo; Prapaporn Boonma; Jian Sha; Ruth Ann Luna; Tor C Savidge; Ashok K Chopra; Sara M Dann
Journal:  mBio       Date:  2020-03-10       Impact factor: 7.867

Review 10.  Challenges for Clinical Development of Vaccines for Prevention of Hospital-Acquired Bacterial Infections.

Authors:  Isabelle Bekeredjian-Ding
Journal:  Front Immunol       Date:  2020-08-05       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.